The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | 12,879 |
| Stock-based compensation | 1,142 |
| Net change in fair value of trading marketable securities | 0 |
| Net change in fair value of digital assets | 62 |
| Non-cash lease expense | 35 |
| Loss on extinguishment of debt | 825 |
| Loss on extinguishment of debt - related party | 333 |
| Amortization of debt discounts and debt issuance costs | 146 |
| Amortization of debt discounts and debt issuance costs - related party | 62 |
| Prepaid expenses and other current assets | -129 |
| Accounts payable and accrued liabilities | 1,308 |
| Accounts payable - related parties | 283 |
| Accrued interest | 48 |
| Accrued interest - related party | 21 |
| Fixed cash payments related to operating leases | -35 |
| Net cash used in operating activities | -8,520 |
| Proceeds from disposition of marketable securities | 0 |
| Purchase of digital assets | 250 |
| Proceeds from disposition of digital assets | -188 |
| Net cash (used in) provided by investing activities | -62 |
| Proceeds from issuance of common shares for cash, net | 6,151 |
| Proceeds from issuance of convertible notes, net | 419 |
| Proceeds from issuance of convertible notes, net - related party | 189 |
| Proceeds from exercise of warrants | 132 |
| Repayment of convertible note | 24 |
| Net cash provided by financing activities | 6,867 |
| Effect of exchange rate changes on cash | -23 |
| Net change in cash and cash equivalents | -1,738 |
| Cash and cash equivalents - beginning of period | 2,338 |
| Cash and cash equivalents - end of period | 600 |
ARTELO BIOSCIENCES, INC. (ARTL)
ARTELO BIOSCIENCES, INC. (ARTL)